Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 12/20 | 0.39 |
| ▸ | IDO1 | P14902 | 10/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6542560 | 0.99 | KMT2A (0.39) | TDO2IDO1KMT2ADHODHMAPT | |
| Hydrochloric Acid SCHEMBL6542516 | 0.78 | TDO2 (0.53) | TDO2IDO1KMT2AMAPTKDM4E | |
| SCHEMBL18512081 | 0.69 | PDE10A (0.46) | DHODHMAPTKDM4EPOLB | |
| SCHEMBL1434290 | 0.68 | MAPT (0.71) | MAPTTDP1KDM4EPOLB | |
| SCHEMBL412162 | 0.67 | NR4A2 (0.57) | KMT2ADHODHMAPTKDM4EPOLB | |
| SCHEMBL30159704 | 0.66 | KDM4E (0.46) | KMT2ADHODHMAPTTDP1KDM4E | |
| SCHEMBL28669617 | 0.66 | KDM4E (0.46) | KMT2ADHODHMAPTTDP1KDM4E | |
| SCHEMBL7619139 | 0.66 | CA12 (0.67) | KMT2AMAPTTDP1KDM4EPOLB | |
| SCHEMBL31009365 | 0.66 | CA12 (0.67) | KMT2AMAPTTDP1KDM4EPOLB | |
| SCHEMBL31042567 | 0.66 | SLC6A4 (0.54) | KMT2AMAPTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324994-A4 | TRICYCLIC COMPOUNDS AND USES THEREOF | CALYX THERAPEUTICS INC (US) | 2004-06-16 | — | — | EP | claimed |
| US-6723736-B2 | FOR THERAPY INFLAMMATION, INFLAMMATORY DISEASES, IMMUNOLOGIC DISEASES AND OTHER DISEASES MEDIATED BY TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) AND/OR INTERLEUKIN 6 OR 10 AND/OR ENZYME CYCLOOXYGENASE-2 (COX-2) | THERACOS, INC. | 2004-04-20 | — | — | US | claimed |
| EP-1324994-A2 | TRICYCLIC COMPOUNDS AND USES THEREOF | Calyx Therapeutics, Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-20020077333-A1 | Tricyclic compounds and uses thereof | THERACOS, INC. | 2002-06-20 | — | — | US | claimed |
| WO-2002030888-A2 | TRICYCLIC COMPOUNDS AND USES THEREOF | CALYX THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1324994-A4 | TRICYCLIC COMPOUNDS AND USES THEREOF | CALYX THERAPEUTICS INC (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1324994-A2 | TRICYCLIC COMPOUNDS AND USES THEREOF | Calyx Therapeutics, Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030888-A2 | TRICYCLIC COMPOUNDS AND USES THEREOF | CALYX THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077333-A1 | Tricyclic compounds and uses thereof | IL6, TNF, IL2 | TDO2 1098/4885IDO1 66/4885KMT2A 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.